PET/MR in Breast Cancer
- PMID: 26050658
- DOI: 10.1053/j.semnuclmed.2015.03.003
PET/MR in Breast Cancer
Abstract
Breast cancer is an international public health concern in which an optimal treatment plan requires a precise staging. Both MRI and PET imaging techniques have made significant progress in the last decades with constant improvements that made both modalities clinically relevant in several stages of breast cancer management and follow-up. On one hand, specific breast MRI permits high diagnostic accuracy for local tumor staging, and whole-body MRI can also be of great use in distant staging, eventually accompanied by organ-specific MRI sequences. Moreover, many different MRI sequences can be performed, including functional MRI, letting us foresee important improvements in breast cancer characterization in the future. On the contrary, (18)F-FDG-PET has a high diagnostic performance for the detection of distant metastases, and several other tracers currently under development may profoundly affect breast cancer management in the future with better determination of different types of breast cancers allowing personalized treatments. As a consequence PET/MR is a promising emerging technology, and it is foreseeable that in cases where both PET and MRI data are needed, a hybrid acquisition is justified when available. However, at this stage of deployment of such hybrid scanners in a clinical setting, more data are needed to demonstrate their added value beyond just patient comfort of having to undergo a single examination instead of two, and the higher confidence of diagnostic interpretation of these co-registered images. Optimized imaging protocols are still being developed and are prone to provide more efficient hybrid protocols with a potential improvement in diagnostic accuracy. More convincing studies with larger number of patients as well as cost-effectiveness studies are needed. This article provides insights into the current state-of-the-art of PET/MR in patients with breast cancer and gives an outlook on future developments of both imaging techniques and potential applications in the future.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
-
Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.Acta Radiol. 2015 Aug;56(8):917-23. doi: 10.1177/0284185114539786. Epub 2014 Jul 10. Acta Radiol. 2015. PMID: 25013091
-
Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.Eur J Radiol. 2014 Feb;83(2):289-96. doi: 10.1016/j.ejrad.2013.11.002. Epub 2013 Nov 23. Eur J Radiol. 2014. PMID: 24331845
-
Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.Q J Nucl Med Mol Imaging. 2013 Dec;57(4):352-66. Q J Nucl Med Mol Imaging. 2013. PMID: 24322792 Review.
-
Diffusion-weighted imaging as part of hybrid PET/MRI protocols for whole-body cancer staging: does it benefit lesion detection?Eur J Radiol. 2013 May;82(5):877-82. doi: 10.1016/j.ejrad.2013.01.019. Epub 2013 Feb 18. Eur J Radiol. 2013. PMID: 23428414
-
Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.Top Magn Reson Imaging. 2007 Jun;18(3):193-202. doi: 10.1097/RMR.0b013e318093e6bo. Top Magn Reson Imaging. 2007. PMID: 17762383 Review.
Cited by
-
Best treatment options for occult breast cancer: A meta-analysis.Front Oncol. 2023 May 12;13:1051232. doi: 10.3389/fonc.2023.1051232. eCollection 2023. Front Oncol. 2023. PMID: 37251927 Free PMC article.
-
Radiogenomics, Breast Cancer Diagnosis and Characterization: Current Status and Future Directions.Methods Protoc. 2022 Oct 3;5(5):78. doi: 10.3390/mps5050078. Methods Protoc. 2022. PMID: 36287050 Free PMC article. Review.
-
Prospective comparison of CT and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients: Initial results.PLoS One. 2021 Dec 2;16(12):e0260804. doi: 10.1371/journal.pone.0260804. eCollection 2021. PLoS One. 2021. PMID: 34855886 Free PMC article.
-
Circulating tumor cells as Trojan Horse for understanding, preventing, and treating cancer: a critical appraisal.Cell Mol Life Sci. 2020 Sep;77(18):3671-3690. doi: 10.1007/s00018-020-03529-4. Epub 2020 Apr 24. Cell Mol Life Sci. 2020. PMID: 32333084 Free PMC article. Review.
-
Prospective evaluation of whole-body MRI and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients.Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2816-2825. doi: 10.1007/s00259-020-04801-2. Epub 2020 Apr 24. Eur J Nucl Med Mol Imaging. 2020. PMID: 32333068 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials